- recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS- 986205, Followed by Continued Post- Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer
This study is looking at new ways to treat bladder cancer that has grown into the muscle. It compares standard chemotherapy with chemotherapy plus new immunotherapy drugs (like Nivolumab) before and after surgery, to see which approach works best and is safest.
Germany · Norway · France - recruitingPHASE2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This study is looking at a new treatment called HER3-DXd for people with certain advanced solid tumours that haven't responded to other treatments. It aims to see how well it works and if it's safe for different types of cancer, like melanoma, lung cancer, and breast cancer.
United States · Australia · Belgium - completedNot Applicable
Imperial Bladder 1 - Fluorescence COnfocal Microscopy for raPid evaluation of detrusor muscle at primary transurethraL rsEctTion of bladdEr tumours (IB1-LaserCOMPLETE)
When doctors remove bladder tumours, checking for bladder muscle in the sample is vital for planning treatment. Currently, test results take weeks, and missing muscle can mean having another operation. This trial tests a fast scanner in the operating room to see if it can quickly confirm that muscle was collected.
United Kingdom · England - recruitingPhase I and Phase II (Integrated)- Other
CA209-8KX Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy
This study is looking at a new way to give nivolumab, a cancer medicine, through an injection under the skin. It's for people with various advanced cancers like lung, kidney, and liver cancer, to see how the body handles the medicine and if it's safe.
Spain · Netherlands · Italy - recruitingPHASE3
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
This study is testing a new medicine, Sacituzumab Tirumotecan (Sac-TMT), for advanced bladder cancer that has worsened after other treatments. Researchers want to see if Sac-TMT helps people live longer compared to standard chemotherapy.
United States · Argentina · Australia - recruitingPHASE1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
This study is testing a new drug, LY4052031, for people with advanced cancers like bladder, breast, and lung cancer. It aims to see if the drug is safe, what dose works best, and if it helps shrink tumors. It's an early-stage study to gather important information.
United States · Australia · China - recruitingPHASE2
Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer
This study looks at whether a medication called dutasteride can stop bladder cancer from coming back in patients with a common type of early bladder cancer. It builds on the understanding that this type of cancer often returns and we want to find effective ways to manage it.
Canada - active not recruitingPHASE3
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
This study compares a new drug combination (enfortumab vedotin plus pembrolizumab) with standard chemotherapy for bladder cancer that has spread to the muscle. It aims to see if the new combination, given before surgery, works better and is safe.
United States · Argentina · Australia - recruiting
Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
This study is looking at a new way to give radiotherapy using a special machine called ETHOS. It aims to make radiotherapy more accurate by adjusting treatment daily for cancers like prostate or head and neck, potentially improving how well it works and reducing side effects.
Germany - active not recruitingPHASE1, PHASE2
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
This study explores new ways to treat bladder cancer, specifically a type that has grown into the bladder muscle. Researchers are testing a new treatment, intismeran autogene, with an existing cancer drug, pembrolizumab, to see if it can stop the cancer from coming back after surgery.
United States · Australia · Canada - recruiting
Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.
This study looks at whether we can find signs of non-bowel cancers, like lung or pancreatic cancer, in a small sample of mucus taken from a person's bottom. We're testing a new, simple device to see if it can help detect these cancers earlier.
United Kingdom - enrolling by invitation
Supporting Sexual Recovery in Women With Bladder Cancer
This study explores how bladder cancer and its treatment, like bladder removal, affect women's sexual well-being. It aims to create tools for healthcare workers to better support women in their recovery, ensuring this important aspect of life is not overlooked.
United Kingdom - recruiting
Cancer Loyalty Card Study 2 (CLOCS-2)
This study looks at shopping habits using loyalty card data from Tesco or Boots to see if certain purchases might hint at cancer earlier. It aims to help doctors diagnose pancreatic, bowel, oesophageal, stomach, liver, bladder, womb, vulval, and ovarian cancers sooner.
United Kingdom - recruiting
A Study of Ward Admissions for Haematuria
This study looks at how hospitals in the UK and other countries manage patients who come in with blood in their pee (haematuria). The aim is to find the best ways to treat this condition and improve care for everyone.
United Kingdom - recruitingPHASE1, PHASE2
DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr
This study, called DURANCE, is testing a new combination treatment for bladder cancer that hasn't spread into the muscle. It combines a vaccine (S-488210/S-488211) with an immunotherapy drug (durvalumab) to see if it's safe and effective in people who haven't responded well to previous treatments.
United Kingdom - active not recruitingPHASE3
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
This study looks at a new treatment called cretostimogene grenadenorepvec for a type of bladder cancer that hasn't spread into the muscle. It compares giving this treatment after surgery to just monitoring patients. The aim is to see if the new treatment can stop the cancer from coming back.
United States · Canada - not yet recruitingNA
Relevance of the Urine Bacterial Culture Performed Before TransUrethral Resection of the Bladder for Post-operative Febrile Urinary Tract Infections Prevention: a Non-inferiority Randomized Controlled Trial
This study looks at whether routine urine tests before bladder cancer surgery (TURB) are truly needed. It's comparing if skipping this test is as safe as doing it, aiming to reduce unnecessary antibiotic use and its risks.
France - recruitingPHASE3
Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)
This study looks at treating a rare kidney or ureter cancer with chemotherapy before surgery. It aims to see if this approach, similar to what's done for bladder cancer, can improve outcomes. We're also checking if enough people can join this type of trial.
Canada - active not recruitingPHASE3
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients
This study looks at a new combination treatment for a type of early bladder cancer. It compares giving a standard treatment called BCG alongside a new drug called atezolizumab to just giving BCG alone. The aim is to see if the combination works better at preventing the cancer from coming back.
Belgium · France · Spain - active not recruitingPHASE2
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
This study is looking at whether a drug called durvalumab, given after surgery, chemo, and radiotherapy, can help people with bladder cancer. We want to see if it stops the cancer from growing or helps cancer cells die.
Canada · Spain · United Kingdom - recruitingPHASE1
A Study of MGC026 in Participants With Advanced Solid Tumors
This study is testing a new medicine called MGC026 for people with advanced cancers that have come back or spread. Doctors want to see if it's safe, what side effects it causes, and if it can help slow down or shrink tumors.
United States · Australia · United Kingdom - recruitingNA
The Man Van Project
The Man Van project offers mobile health checks at workplaces and communities for men, especially those from ethnic minority groups, to find health problems like prostate cancer early. The goal is to make healthcare easier to access and improve men's health outcomes.
United Kingdom - active not recruitingPHASE2
Study of Tumour Focused Radiotherapy for Bladder Cancer
This study looks at new ways to give radiotherapy for bladder cancer that has grown into the bladder wall. It compares standard treatment with new methods that focus the radiation more precisely on the tumour. The aim is to see if these new methods work better and have acceptable side effects.
Australia · New Zealand · United Kingdom - recruitingPHASE1, PHASE2
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
This study is testing new treatments for a type of bladder cancer that has spread or can't be removed, called urothelial cancer. Researchers want to see if adding new medicines to standard treatment is safe and if it helps shrink the cancer.
United States · Chile · France - active not recruitingPHASE1, PHASE2
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
This study is looking into a new drug, AZD5305, by itself or with other cancer treatments, for advanced solid cancers like ovarian, breast, and lung cancer. It aims to see if it's safe, tolerable, and effective.
United States · Australia · Canada - active not recruitingPHASE1, PHASE2
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This study is testing a new drug, HMBD-001, for advanced cancers where a protein called HER3 is active. We want to find the best dose, understand side effects, and see if it helps stop cancer growth, sometimes with another drug called enzalutamide.
United Kingdom - recruitingPHASE1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
This study is looking at a new medicine called PF-08046876 for people with advanced cancers like bladder, lung, head & neck, oesophageal, or pancreatic cancer. It checks how safe the medicine is and how well it works. The medicine is given through a drip.
United States · Canada · China - recruiting
Ex VIvo DEtermiNed Cancer Therapy
This study, called EVIDENT, wants to see if we can test a tiny piece of your tumour in the lab to predict how well cancer treatments will work for you. It's for people with various solid cancers, like bladder or kidney cancer, who are having surgery or a biopsy.
United Kingdom - recruitingNA
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
This study looks at adding special radiation to standard care for rare cancers that have spread a little. It wants to see if this addition helps people live longer compared to standard care alone.
Belgium · France · Germany - recruiting
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
The MOMENTUM Study is tracking how a new type of advanced radiotherapy, called MR-Linac, works for people with different cancers. It aims to see if this treatment improves survival, controls cancer better, and enhances quality of life by using highly precise radiation guidance.
United States · Australia · Belgium - active not recruitingPHASE3
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
This study looks at new treatments for a type of bladder cancer that hasn't spread into the muscle. It compares new drugs, TAR-200 (alone or with Cetrelimab), against the usual treatment, BCG, to see which works best and is safest.
United States · Argentina · Australia